» Articles » PMID: 39103364

Deciphering the Genetics and Mechanisms of Predisposition to Multiple Myeloma

Abstract

Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel. Through functional fine-mapping and Mendelian randomization, we uncover two causal mechanisms for inherited MM risk: longer telomeres; and elevated levels of B-cell maturation antigen (BCMA) and interleukin-5 receptor alpha (IL5RA) in plasma. The largest increase in BCMA and IL5RA levels is mediated by the risk variant rs34562254-A at TNFRSF13B. While individuals with loss-of-function variants in TNFRSF13B develop B-cell immunodeficiency, rs34562254-A exerts a gain-of-function effect, increasing MM risk through amplified B-cell responses. Our results represent an analysis of genetic MM predisposition, highlighting causal mechanisms contributing to MM development.

Citing Articles

Germline predisposition in multiple myeloma.

Rodrigues F, Jasielec J, Perpich M, Kim A, Moma L, Li Y iScience. 2025; 28(1):111620.

PMID: 39845416 PMC: 11750583. DOI: 10.1016/j.isci.2024.111620.


Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes.

Thibaud S, Subaran R, Newman S, Lagana A, Melnekoff D, Bodnar S Blood Cancer Discov. 2024; 5(6):428-441.

PMID: 39283238 PMC: 11528192. DOI: 10.1158/2643-3230.BCD-23-0208.


A Role for Germline Variants in Multiple Myeloma?.

Walker B Blood Cancer Discov. 2024; 5(6):375-376.

PMID: 39283233 PMC: 11528183. DOI: 10.1158/2643-3230.BCD-24-0226.

References
1.
Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597. PMC: 6097138. DOI: 10.1182/blood-2018-03-840132. View

2.
Vanegas S, Ramirez-Montano D, Candelo E, Shinawi M, Pachajoa H . DeSanto-Shinawi Syndrome: First Case in South America. Mol Syndromol. 2018; 9(3):154-158. PMC: 6006642. DOI: 10.1159/000488815. View

3.
Li N, Johnson D, Weinhold N, Kimber S, Dobbins S, Mitchell J . Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell Rep. 2017; 20(11):2556-2564. PMC: 5608969. DOI: 10.1016/j.celrep.2017.08.062. View

4.
Amend S, Wilson W, Chu L, Lu L, Liu P, Serie D . Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. PLoS One. 2015; 10(5):e0127828. PMC: 4447437. DOI: 10.1371/journal.pone.0127828. View

5.
Morgan G, Davies F, Gregory W, Bell S, Szubert A, Navarro Coy N . Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2011; 97(3):442-50. PMC: 3291601. DOI: 10.3324/haematol.2011.043372. View